Betting on the FDA: How Kalshi’s Biotech Prediction Markets Work, and What They Mean for $XBI, $IBB and the Sector

01What happened on July 16

On Thursday, July 16, 2026, Kalshi, one of the largest prediction-market exchanges in the world, announced it would begin listing contracts on clinical trial outcomes and FDA decisions. Its technical partner is AppliedXL, a public-intelligence company that monitors and structures clinical and regulatory records. For the first time, the probability that a drug clears Phase 3 or wins FDA approval becomes a public, continuously updated price that anyone can read.

This is not a story about a single stock. It is a story about market infrastructure: it changes the kind of information available to anyone who follows biotech catalysts. That is why it deserves a careful reading rather than being dismissed as one more extension of online gambling.

This article covers, in order: how a prediction market works mechanically, who Kalshi is and under what authority it operates, what exactly launched, how a contract’s outcome gets decided, the serious arguments for and against, the paradox neither side resolves, and finally the practical part: who can actually open an account and on what terms. One point up front, because it reframes everything else for many readers: 54 jurisdictions, including Canada, the United Kingdom, France and Italy, appear on Kalshi’s restricted list and cannot trade at all.

02What a prediction market is, in plain terms

A prediction market is an exchange where you do not buy shares in companies. You buy contracts tied to whether a specific event happens. Each contract is binary: it pays $1 if the event occurs and $0 if it does not. There is no middle ground.

That structure produces the property that makes these markets interesting. If a contract trades at 72 cents, a buyer is paying $0.72 for the chance to receive $1 if the event resolves YES. Divide the price by the payout and you read it directly as an implied probability: roughly 72%. You do not need a model to interpret it. You move the decimal point.

The difference from buying a biotech stock is substantial, and it is Kalshi’s main commercial argument. When you buy the equity you buy the whole company: management, cash, the rest of the pipeline, dilution risk, sector sentiment, macro. You can be right about the science and still lose money because the company raised capital the day after positive data. The contract isolates one question: did that trial hit its endpoint, yes or no.

AppliedXL itself tempers that promise in its own documentation: a contract “does not perfectly isolate the underlying science,” because the price also reflects liquidity, participation, timing, sentiment and contract design. That is an honest qualification that most marketing material does not volunteer, and it is worth keeping in mind.

03Who Kalshi is and under what authority it operates

Kalshi is not an offshore bookmaker. It is KalshiEX, LLC, an exchange registered with the U.S. Commodity Futures Trading Commission as a Designated Contract Market, the same regulatory category as futures exchanges. The CFTC is an independent U.S. government agency that has overseen derivatives markets since 1974 and answers to Congress. Kalshi received its DCM designation in November 2020.

That status is the central fact of the story. It means Kalshi’s contracts are event-based financial derivatives rather than wagers in the legal sense, and that the exchange carries obligations for market surveillance, investigation, enforcement and regulatory reporting. It also means the perimeter is entirely American: the CFTC defines what is permitted, not a European authority.

The company by the numbers

Kalshi closed a $1 billion Series F in May 2026, led by Coatue, at a $22 billion valuation, up from $11 billion in late 2025 — a doubling in roughly six months. Sequoia, a16z, Paradigm, IVP, Morgan Stanley and ARK Invest participated. The platform reports more than 5 million users and had passed $52 billion in event-contract volume as of March 2026; 2025 fee revenue was $263.5 million. In 2026 the company appeared on the TIME100 list of most influential companies.

That aggregate volume comes from the platform’s full range of markets, spanning sports, politics, economic data, index and crypto contracts. Biotech is a recent graft and, as noted, still marginal in dollar terms.

04What exactly launched

The program is explicitly a pilot, with a deliberately narrow perimeter. You cannot trade any drug at any stage. The admission rules, set by Kalshi with AppliedXL, are three, and they are worth reading closely because they explain most of what follows.

1. Late-stage trials only. Contracts are listed only on Phase 3 trials run by established biopharma companies, and only on full FDA approval decisions. No Phase 1 or 2, no conditional approvals. The stated rationale: earlier-phase studies involve exploratory endpoints and greater insider-trading risk, while late-stage trials publicly register their primary endpoint, often agreed with the FDA in advance, which makes resolution unambiguous.
2. Listing only after enrollment closes. A contract is listed only after a trial has finished enrolling patients. The reason is explicitly ethical rather than financial: a visible price could influence physician referrals and patients’ decisions to participate. By requiring enrollment to close first, that channel of influence is shut off.
3. Employment verification for everyone. Kalshi requires employment verification for anyone trading these specific markets. It is a measure the exchange does not apply elsewhere, designed to catch people working inside the ecosystem of the drug in question.

The contracts already open

At launch there were a little over a dozen markets, concentrated on late-stage trials at companies with market caps of at least $500 million. Among those cited by Kalshi and the press:

• The POLARIS-AD Phase 3 trial of AR1001, an AriBio drug for early-stage Alzheimer’s disease, and whether it will meet its primary endpoint.
• FDA approval of anito-cel from Gilead $GILD and Arcellx $ACLX for relapsed/refractory multiple myeloma, with a year-end deadline.
• The approval timing of retatrutide, Eli Lilly’s $LLY new weight-loss drug.
• One very long-dated contract: will the FDA approve a cure for Type 1 diabetes before 2033? As of July 16 the contract priced the NO outcome at around 56%.

05How the outcome gets decided: the resolution chain

This is the technically most interesting part, and what separates the project from a wager. The underlying problem is familiar to anyone who follows biotech: trial results almost never arrive in a single definitive document. They come out in pieces, scattered across registries, regulatory filings and company statements, and press releases tend to put a favourable spin on data that, read closely, say something else.

To handle this, the resolution chain runs through six steps. It is worth knowing even independently of prediction markets, because it is precisely the process anyone reading a trial press release ought to follow.

Two details deserve emphasis. First: the criteria for reading the document are defined before the contract opens for trading, not after results arrive. That is the structural guarantee against the temptation to reinterpret the rules once the outcome is known. Second: AI handles monitoring, document classification and information extraction, but no contract is finally adjudicated solely on an automated reading. Human review always applies, and the final call belongs to the exchange.

AppliedXL also does not use identifiable patient data, confidential clinical records, material nonpublic information, analyst commentary or private communications. Resolution rests exclusively on the public sources named in the contract. And AppliedXL employees are barred by company policy from trading prediction markets at all, not merely the contracts the firm supports.

06The case in favour

The information problem is real

Kalshi’s thesis starts from a hard-to-dispute observation. The probability that a drug reaches market is among the most valuable numbers in the economy, and among the least visible. McKinsey estimates the average cost of bringing a single drug to market at $2.3 billion, and a company’s fortunes can turn on one result.

Those estimates exist: pharmaceutical companies, investment banks, institutional investors and expert networks all produce them. They simply stay behind closed doors, or behind a paywall few can afford. Anyone without access to those resources operates with structurally inferior information.

There is a historical precedent, and it comes from inside the industry

In 2003 Eli Lilly asked roughly fifty chemists, biologists and project managers to trade shares tied to six drug candidates. The internal market identified the three that would go on to be the most successful. The experiment stayed limited in scope, but it is the most-cited example of how a market can surface knowledge dispersed inside an organization, including views that never travel up the conventional forecasting chain.

Isolating the question has analytical value

For catalyst followers, the value is not necessarily trading these contracts. It is having a public number to push against. If a stock prices one outcome and the contract prices another, the gap is information: either the equity market is discounting something else as well, or one of the two signals is wrong. Either way, there is something to understand.

07The case against

The objections do not come from generic moralists. They come from bioethicists, physicians and clinical trial researchers. They are technical arguments and deserve to be taken as seriously as the case in favour.

Financial incentives reaching people with power over the study

The heaviest criticism, reported by STAT News, is that financial incentives could push people with influence over a study to alter or delay decisions. You do not need to imagine outright fraud: an analysis decision taken at one moment rather than another, a disclosure moved forward or back by a few days, a choice about how to handle missing data. The shift, researchers warn, runs from producing accurate medical evidence toward influencing a market outcome.

Effects on patients

A visible price can influence already-enrolled patients, who might decide to withdraw from or stay in a study based on the odds rather than medical advice. The post-enrollment listing rule protects the recruitment phase but does nothing for someone already in the study watching the price fall. AppliedXL acknowledges the point explicitly: a market price does not establish whether a treatment is safe, effective or appropriate for an individual patient, and should never be used to decide whether to join, remain in or leave a trial.

Insider trading is hard to stop

Kalshi prohibits trading by anyone holding material nonpublic information and has published a detailed list of excluded categories: officers and employees of the manufacturer and its affiliates, members of independent data monitoring committees with access to unblinded data, principal investigators and site staff, employees of CROs and central labs, staff at the FDA, EMA and other regulators with access to nonpublic documents, ethics committee members, bankers and advisors with access to confidential clinical data, people under expert-network agreements, and immediate family and household members of all of the above.

It is a serious list. But AppliedXL itself, asked whether employment verification eliminates insider-trading risk, answers in a single word: no. A person can obtain material nonpublic information through consulting work, vendors, professional relationships or household members, channels an employer’s name does not reveal.

There is also a timing asymmetry no surveillance system resolves: even if regulators detect the abuse later, the trial may already have been compromised. Enforcement arrives after the fact; the damage to the research, if any, has already happened.

The risk that a price gets mistaken for evidence

This is the subtlest risk and perhaps the likeliest. A public number, continuously updated, with the appearance of market data, carries an authority it has not earned. A contract at 72% will get quoted as “the market says there is a 72% chance of approval,” and through repetition it becomes a fact. It is not: it is the price at which a small group of people are trading right now, on a thin book.

08The paradox neither side resolves

Here is the interesting tension, the one that does not appear in the press releases.

The project’s promise is to make public an information that is currently private. But the mechanism meant to produce that information works only if participants know something. A prediction market is accurate to the extent that it aggregates dispersed knowledge: people who understand the mechanism of action, who have read the literature, who watched other trials in the same indication fail for the same reason. The more competent participants, the better the signal.

The problem is that in biotech, the people most competent on a specific trial are also the people closest to that trial. And those are precisely the categories Kalshi must exclude to protect the integrity of the market and of the research. The result is a structural tension: the exclusions required for integrity remove exactly the knowledge that would make the price informative.

Add the liquidity constraint. With $128,401 in total volume on launch day, a single participant with a few thousand dollars can move the price noticeably. A price that moves because of an order rather than because of information is not a signal; it is noise that looks like one. This may improve as volumes grow, but until it does the number deserves considerable caution.

It should be acknowledged that Kalshi and AppliedXL hide none of these limits. The pilot is explicitly narrow, the documentation concedes the risks cannot be fully eliminated, and both companies say they intend to study how the markets behave and revise the design before any broader release. That is more cautious than one might expect. It remains true that the experiment runs on real events, with real patients inside the trials.

09How to take part, and who cannot

Now the practical part. Before any consideration of accounts, deposits and fees, there is one filter that decides everything else: your jurisdiction of residence.

The geographic filter: restricted jurisdictions

The Kalshi Member Agreement, the contract you accept when opening an account, contains at Section VI an explicit list of “Restricted Jurisdictions.” Anyone domiciled, organized or located in one of those countries is prohibited from accessing, using or trading contracts on the platform. This is not a grey area: it is written into the agreement.

It is worth noting what is not on the list, because it is equally telling: Germany, Spain, the Netherlands, Austria, Sweden, Denmark, Greece, Romania and the Czech Republic do not appear among the restricted jurisdictions. The dividing line is therefore not “EU yes, EU no”: it is a patchwork reflecting individual national regimes on event derivatives and gambling. The document should still be re-read in its current version before drawing conclusions, since Kalshi can amend it unilaterally on notice.

Kalshi states in writing that verifying the lawfulness of access is an individual responsibility and that it does not provide legal or eligibility advice to individual users. In plain terms: you cannot lean on the fact that the platform let you open an account.

For residents of a permitted jurisdiction

There are two baseline requirements: being at least 18 years old and passing document verification if requested. During signup you confirm your country of residence and verify your identity. Kalshi is required to collect this information to comply with U.S. law and CFTC regulations, plus obligations under the USA PATRIOT Act, which requires obtaining, verifying and recording customer identifying information.

In the U.S., verification typically requires a Social Security number, government-issued photo ID and proof of address. For permitted international users identity verification is still required but protocols are less stringent. A U.S. phone number is not needed: Kalshi supports country codes from most countries, though some are unsupported.

For these specific biotech markets there is an added step: employment verification, mandatory for all participants. It does not exist on the platform’s other contracts.

Deposits and withdrawals

Available methods differ substantially between U.S. and international users. Permitted international users can use debit cards (Visa and Mastercard only), wire transfer with a $1,000 minimum, and cryptocurrency. ACH transfers, PayPal and Venmo are not available to them. For withdrawals, international users can use debit card or crypto.

On costs: there are no membership fees and no settlement fees. ACH deposits and withdrawals are free. Kalshi charges nothing extra on incoming wires, while wire withdrawals are not supported below $500,000. On cards, Kalshi charges a maximum 2% fee on deposits. Crypto deposits and withdrawals may carry third-party payment processor fees, disclosed before the transaction.

Trading fees

The structure here is less intuitive than it looks, and worth understanding because it bites hardest on mid-probability contracts. Fees apply only to orders that match immediately against orders already resting on the book. Orders that rest unmatched pay no fee, except in markets subject to maker fees, and cancelling a resting order costs nothing.

The general formula, effective February 5, 2026, is: fee = round up of 0.07 x C x P x (1-P), where P is the contract price in dollars and C the number of contracts. The maker fee uses the same shape with a 0.0175 coefficient.

The practical consequence of that P x (1-P) term is that the cost peaks when the contract sits at 50 cents, precisely when the outcome is most uncertain, and falls toward the extremes. Here are points from the official table, per 100 contracts:

On a 50-cent contract the fee is 3.5% of the capital committed at entry ($1.75 on $50 of notional), and another is paid on exit, calculated at the exit price. Across repeated trades that is meaningful friction, to be weighed against whatever informational edge one believes one has. S&P 500 and Nasdaq-100 markets carry a halved schedule, but that does not apply to biotech contracts.

10A tool: how to read a prediction-market price in five questions

This is the part to take away, useful even to someone who will never open an account. When you see “the market says there is an X% chance” quoted in a forum, an article or a social post, run the number through these five questions before giving it weight.

1. What is the volume on that specific contract? Not platform volume, not category volume: the individual contract. If it is a few thousand dollars, the price tells you what a handful of people think. On thin books, a single trade moves the quote more than any news does.
2. What exactly is the contract asking? “Will the FDA approve drug X by December 31” and “Will the FDA approve drug X” are different questions. The first resolves NO even if approval comes on January 3. Many apparent gaps between price and analyst consensus are really differences in deadline.
3. What is the resolution source? The contract names a specific controlling source: the ClinicalTrials.gov record, the FDA approval letter, the advisory committee vote record. The price prices that source, not the general impression around the drug. A trial can meet a statistical endpoint without establishing clinical significance, and a successful trial does not necessarily lead to approval.
4. Did the price move on information or on an order? If the move is not accompanied by a dated public document, the default assumption is flow, not information. Look for the document before building a thesis on it.
5. What is the stock saying at the same moment? If contract and equity diverge, before concluding that one is wrong, remember the equity also discounts cash, dilution, the rest of the pipeline and the sector. The divergence is often explainable, and understanding why is worth more than the number itself.

11What changes for catalyst followers

Ethical judgement aside, three concrete consequences are worth watching over the coming months.

A second thermometer alongside the stock

Until now, gauging how the market priced a catalyst meant looking at the stock, options implied volatility and analyst consensus. If these contracts gain liquidity, a direct read on the single regulatory question gets added. It is one more data point to compare against the others, not to replace them.

Where the contracts and the biotech ETFs intersect

Anyone following the sector rather than a single name usually does so through two instruments: $XBI, the SPDR S&P Biotech ETF, which tracks a modified equal-weighted index and therefore spreads exposure across large, mid and small caps, and $IBB, the iShares Biotechnology ETF, built on the Nasdaq Biotechnology index and therefore more concentrated in the larger biotech and pharmaceutical names listed on Nasdaq.

The construction difference matters a great deal here. An equal-weighted ETF like $XBI is structurally more sensitive to binary outcomes: a Phase 3 failure at a small cap carries the same index weight as news at a far larger name. $IBB, dominated by the biggest market caps, absorbs any single event more easily. Put differently, what Kalshi’s contracts price event by event is exactly the kind of risk $XBI aggregates and $IBB dilutes.

If liquidity did arrive and the number of contracts grew, the interesting use would not be trading them but reading them together: a cluster of Phase 3 catalysts priced systematically lower than sector positioning implies would say something about the gap between regulatory expectations and equity exposure. That is a scenario, not a forecast, and it needs testing if and when volumes allow.

Perimeters tend to widen

Kalshi says the pilot is narrow and the design will be revised before any broader release. Forbes notes the market could be expanded later. The open question is whether the current safeguards, nearly all of which rest on this being Phase 3 with registered endpoints and closed enrollment, survive an extension toward earlier phases or small caps, where the ratio between bet size and company market cap changes entirely.

Pressure on the quality of the public record

If money settles on ClinicalTrials.gov and FDA documents, attention grows on how complete and timely that record is. The 29.6% of overdue studies with no results posted, reported by the FDA in April 2026, becomes a more visible problem when someone loses money over it. That may be the most useful side effect of the whole exercise, and it is also the least publicized.

12Bottom line

Kalshi has brought inside a federally regulated perimeter something that previously existed only behind closed doors: a public probability on clinical and regulatory outcomes. The technical framework is more serious than the headline “betting on drugs” suggests, with resolution criteria fixed before trading opens, public sources named in the contract, human review, and separation between the party that analyzes and the party that decides.

At the same time the limits are structural rather than transitional. Liquidity today is thin enough to make the signal unreliable precisely when it will be quoted most. The exclusions required for integrity remove from the market the knowledge that would make it informative. And the risk of a price being mistaken for clinical evidence is not theoretical: it is how numbers circulate.

For anyone tracking catalysts, the practical conclusion is this. Access is real but conditional: eligibility runs through the member agreement, which excludes 54 jurisdictions, and through employment verification on these specific markets. Beyond access, the more durable consequence is the arrival of a new public number that will be quoted more and more often around PDUFA dates and readouts, and that is worth knowing how to read, and how to discount, before it hardens into common sense.

The rest will be told by volumes. If in six months these contracts still trade a few hundred thousand dollars, they will have remained a curiosity. If liquidity does arrive, the conversation about risks deserves reopening, because by then the risks will be as real as the signal.